Radionuclide bone imaging.
Radionuclide bone imaging of the skeleton, now well established as the most important diagnostic procedure in detecting bone metastases, is also a reliable method for the evaluation of the progression or regression of metastatic bone disease. The article concentrates on the technetium-99m agents and the value of these agents in the widespread application of low-dose radioisotope scanning in such bone diseases as metastasis, osteomyelitis, trauma, osteonecrosis, and other abnormal skeletal conditions.
D001168:Arthritis / Q000000981:diagnostic imaging; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D004164:Diphosphonates; D005271:Femur Head Necrosis / Q000000981:diagnostic imaging; D050723:Fractures, Bone / Q000000981:diagnostic imaging; D006801:Humans; D007595:Joint Prosthesis; D010001:Osteitis Deformans / Q000000981:diagnostic imaging; D010019:Osteomyelitis / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D013667:Technetium; D017556:Technetium Compounds; D014551:Urinary Tract / Q000000981:diagnostic imaging
D004164:Diphosphonates; D017556:Technetium Compounds; D013667:Technetium; C029045:technetium Tc 99m diphosphonate